Korro Bio, Inc.(KRRO)Earnings, Financials & Key RatiosKorro Bio, Inc. (KRRO) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's cash position of $61.7 million against persistent quarterly operating losses of $20.4 million suggests an imminent liquidity risk that likely necessitates further dilutive equity issuance.
Korro Bio, Inc. (KRRO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Korro Bio, Inc. (KRRO) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $1.69vs $1.60-5.6% | —vs $761,167 |
| Q2 2026 | May 6, 2026 | $1.69vs $1.73+2.1% | —vs $761,167 |
| Q2 2026 | Mar 12, 2026 | $5.32vs $1.93-175.6% | $1Mvs $700,000+85.7% |
| Q4 2025 | Nov 12, 2025 | $1.92vs $2.61+26.4% | $1Mvs $425,000+156.5% |
Recent stock market news and headlines for Korro Bio, Inc. (KRRO)
Korro Bio, Inc. (KRRO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Key metrics vs top competitors for Korro Bio, Inc. (KRRO)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $14.49 | $144.22M | -1.16 | 181.46% | -1834.48% | -110.7% | — | |
| $37.92 | $3.9B | -46.81 | 120.01% | -49.17% | -5.89% | — | |
| $3.75 | $367.15M | -2.08 | 25.39% | -281.59% | -677.39% | — | |
| $60.77 | $5.86B | -9.39 | -89.97% | -13856.54% | -30.88% | — | |
| $17.43 | $1.96B | -4.57 | 16.92% | -597.04% | -57.27% | — | |
| $3.99 | $720.66M | -2.96 | 55.28% | -4917.55% | -188.82% | — |
Korro Bio, Inc. (KRRO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Korro Bio, Inc. (KRRO) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 7, 2026·SEC
Mar 12, 2026·SEC
Mar 9, 2026·SEC
Get notified when KRRO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Korro Bio, Inc. (KRRO) stock FAQ — growth, dividends, profitability & financials explained
Korro Bio, Inc. (KRRO) reported $3.8M in revenue for fiscal year 2025.
Korro Bio, Inc. (KRRO) grew revenue by 181.5% over the past year. This is strong growth.
Korro Bio, Inc. (KRRO) reported a net loss of $113.5M for fiscal year 2025.
Korro Bio, Inc. (KRRO) has a return on equity (ROE) of -110.7%. Negative ROE indicates the company is unprofitable.
Korro Bio, Inc. (KRRO) had negative free cash flow of $70.6M in fiscal year 2025, likely due to heavy capital investments.
